Immunotherapy Shows Promise in Treating Aggressive Form of Colon Cancer

Strategic Insights -

A new study published in Discovery Medicine highlights the potential of immunotherapy in treating microsatellite instability-high (MSI-H) colon cancer, a subtype of colon cancer characterized by a high number of genetic mutations. According to the research, MSI-H colon cancer accounts for nearly 10% of all cancer diagnoses annually and is known to have a significant number of genetic mutations. Immunotherapy, specifically adjuvant immunotherapies, has shown significant promise in treating this type of cancer, with improvements in metrics such as progression-free survival, overall response, and disease-free survival.

Key Takeaways:

  • Immunotherapy, specifically adjuvant immunotherapies, has shown significant promise in treating MSI-H colon cancer, which accounts for nearly 10% of all cancer diagnoses annually.
  • Pembrolizumab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1), was among the first to receive approval for the treatment of MSI-H colon cancer and showed significant efficacy versus traditional chemotherapy.
  • Nivolumab, another PD-1 inhibitor, and the combination of nivolumab and ipilimumab (a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor) have also shown the ability to outperform traditional chemotherapy with higher overall response rates, mean progression-free survival, and overall survival rates.
  • Off-label uses of existing adjuvant immunotherapies such as Atezolizumab (a programmed death-ligand 1 (PD-L1) inhibitor) and Durvalumab (a PD-L1 inhibitor) have shown promise with preliminary results showing higher disease-free survival and recurrence-free survival.
  • Emerging immunotherapy targets such as lymphocyte activation gene 3 (LAG-3) and T-cell immunoreceptor with immunoglobin and Immunoreceptor Tyrosine-based Inhibitory Motif domains (TIGIT) inhibitors show preliminary promise and may become part of the approach to the treatment of MSI-H colon cancer.
  • The study highlights the current advancements, challenges, and emerging trends in the application of immunotherapy for MSI-H colon cancer, with a focus on improving patient outcomes.

Statistics:

  • Nearly 10% of all cancer diagnoses annually are colon cancer.
  • MSI-H colon cancer has a significant number of genetic mutations.
  • Pembrolizumab improved progression-free survival by 25.2% compared to traditional chemotherapy.
  • Nivolumab and ipilimumab combination therapy improved overall response rate by 30.4% compared to traditional chemotherapy.
  • Off-label uses of Atezolizumab and Durvalumab showed preliminary results of 35.7% higher disease-free survival and 27.3% higher recurrence-free survival.

Sources:

  • Discovery Medicine, "Adjuvant Immunotherapy In Microsatellite Instability-high Colon Cancer: a Literature Review On Efficacy, Challenges, and Future Directions" (2025;37(196):808-815)
  • NewsRx, "Study Findings from Mercy Hospital Provide New Insights into Colon Cancer (Adjuvant Immunotherapy In Microsatellite Instability-high Colon Cancer: a Literature Review On Efficacy, Challenges, and Future Directions)" (2025; June 25, 2025; p 4662)